Amgen through its wholly-owned subsidiary Pillartree has agreed to acquire Ireland-based biopharmaceutical firm Horizon Therapeutics for an enterprise value of around $28.3bn. The US biotechnology company will pay $116.5 per share in cash, which is a premium of around 19.7% to Horizon Therapeutics’ closing stock price of $97.29 per share on 9 December 2022. Horizon […]
Horizon Therapeutics, an Irish biopharma company, has agreed to acquire Viela Bio, a US-based biotech company, for $53 per share in cash or about $3.05 billion in a move to significantly expand its development pipeline and grow its rare disease medicine portfolio. Viela Bio is focused on developing and commercializing therapies for a wide variety […]
Uplizna FDA approval : US biotech company Viela Bio has secured approval from the US Food and Drug Administration (FDA) for Uplizna (inebilizumab-cdon) injection for intravenous use for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease of the central nervous system (CNS). The approval of Uplizna is for neuromyelitis optica spectrum […]